Published in Front Immunol on January 12, 2015
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
T cell metabolic fitness in antitumor immunity. Trends Immunol (2015) 1.12
Understanding the Intersections between Metabolism and Cancer Biology. Cell (2017) 0.94
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
Role of neuroinflammation in the emotional and cognitive alterations displayed by animal models of obesity. Front Neurosci (2015) 0.85
Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology (2016) 0.84
Learning from other diseases: protection and pathology in chronic fungal infections. Semin Immunopathol (2015) 0.84
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity. Vaccines (Basel) (2015) 0.83
Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol (2016) 0.83
Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J Biol Chem (2015) 0.81
Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation. Clin Cancer Res (2016) 0.81
Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer. Transl Res (2015) 0.80
The Role of CD4 T Cell Memory in Generating Protective Immunity to Novel and Potentially Pandemic Strains of Influenza. Front Immunol (2016) 0.79
The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals. Front Immunol (2015) 0.78
Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase. Sci Rep (2016) 0.78
Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment. Front Immunol (2017) 0.77
New Cyclic Lipopeptides of the Iturin Class Produced by Saltern-Derived Bacillus sp. KCB14S006. Mar Drugs (2016) 0.77
Evasion of Host Immune Defenses by Human Papillomavirus. Virus Res (2016) 0.77
Antibody-based immunotherapy of solid cancers: progress and possibilities. Immunotherapy (2015) 0.77
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells. Mol Pharmacol (2016) 0.77
IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. Oncotarget (2016) 0.76
Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1. J Cell Mol Med (2016) 0.76
Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis. Front Immunol (2016) 0.76
The Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy. Int J Tryptophan Res (2016) 0.76
Alcohol exposure differentially effects anti-tumor immunity in females by altering dendritic cell function. Alcohol (2016) 0.75
Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas. Oncoimmunology (2017) 0.75
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget (2016) 0.75
EWS-FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway. FEBS Lett (2016) 0.75
Leucine Metabolism in T Cell Activation: mTOR Signaling and Beyond. Adv Nutr (2016) 0.75
Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. Sci Rep (2017) 0.75
Identification of an evolutionary conserved structural loop that is required for the enzymatic and biological function of tryptophan 2,3-dioxygenase. Sci Rep (2016) 0.75
Expression and regulation of immune-modulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway epithelial cells and its effect on T cell activation. Oncotarget (2016) 0.75
Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. Int J Tryptophan Res (2017) 0.75
Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. Cell Mol Life Sci (2017) 0.75
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell (2017) 0.75
Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer. Dis Markers (2016) 0.75
Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis. Clin Transl Immunology (2016) 0.75
In search of druggable targets for GBM amino acid metabolism. BMC Cancer (2017) 0.75
Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase. Thyroid (2016) 0.75
Gene Expression Differences in Prostate Cancers between Young and Old Men. PLoS Genet (2016) 0.75
Neutrophils are Essential in Short Hairpin RNA of Indoleamine 2,3- Dioxygenase Mediated-antitumor Efficiency. Mol Ther Nucleic Acids (2016) 0.75
Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol Cell Proteomics (2017) 0.75
The modulation of enzyme indoleamine 2,3-dioxygenase from dendritic cells for the treatment of type 1 diabetes mellitus. Drug Des Devel Ther (2017) 0.75
Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol (2017) 0.75
The Complex Biology of the Aryl Hydrocarbon Receptor and Its Role in the Pituitary Gland. Horm Cancer (2017) 0.75
Aryl hydrocarbon receptor (AHR) is a potential tumour suppressor in Pituitary Adenomas. Endocr Relat Cancer (2017) 0.75
Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 9.32
CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 6.94
Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 5.47
Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 5.26
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 4.63
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 4.53
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Regulation of immune responses by prostaglandin E2. J Immunol (2012) 3.93
Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell (2011) 3.80
An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol (2010) 3.75
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol (1981) 3.02
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity (2013) 2.78
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol (2004) 2.77
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 2.76
Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature (2014) 2.75
Complementation of dominant suppression implicates CD98 in integrin activation. Nature (1997) 2.62
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A (2010) 2.46
The aryl hydrocarbon receptor in immunity. Trends Immunol (2009) 2.19
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene (2008) 1.97
STAT3 signaling: anticancer strategies and challenges. Mol Interv (2011) 1.95
Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun (2008) 1.89
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.65
A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res (2004) 1.64
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 1.58
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2007) 1.48
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One (2011) 1.32
Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain (2009) 1.32
AhR sensing of bacterial pigments regulates antibacterial defence. Nature (2014) 1.30
Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol (2007) 1.23
Inhibition of cytochrome P4501-dependent clearance of the endogenous agonist FICZ as a mechanism for activation of the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2012) 1.19
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget (2014) 1.11
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem (2011) 1.10
The role of L-tryptophan transport in L-tryptophan degradation by indoleamine 2,3-dioxygenase in human placental explants. J Physiol (2001) 1.09
A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol (2006) 1.04
Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim Biophys Acta (2004) 1.02
Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta (2011) 0.96
The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem Pharmacol (1995) 0.87
Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2,3-dioxygenase. Eur J Immunol (2012) 0.87
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia (2014) 0.82
Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase. Biochem Biophys Res Commun (2013) 0.79